# A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

> **NCT07174583** · PHASE1,PHASE2 · RECRUITING · sponsor: **IDEAYA Biosciences** · enrollment: 208 (estimated)

## Conditions studied

- Small-cell Lung Cancer
- Neuroendocrine Carcinomas
- Solid Tumor Show to Express DLL3

## Interventions

- **DRUG:** IDE849
- **DRUG:** durvalumab
- **DRUG:** IDE161

## Key facts

- **NCT ID:** NCT07174583
- **Lead sponsor:** IDEAYA Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2029-05
- **Final completion:** 2029-05
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2026-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174583, "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07174583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*